Moderna shares set to soar after Covid-19 vaccine 95% effective
Moderna shares extend gains after Covid-19 vaccine shows close to 95% efficacy rate in latest trials, with markets bolstered by several coronavirus drugs that could see an end to economic restrictions as early as spring.
- Moderna shares extend gains after Covid-19 vaccine shows nearly 95% efficacy rate
- The US-based biotech will now submit regulatory filings around the world
- Moderna’s drug, along with Pfizer’s own vaccine, help bolster financial markets
Moderna shares extend gains after Covid-19 vaccine shows close to 95% efficacy rate in latest trials, with financial markets bolstered by several coronavirus drugs that could see an end to economic restrictions as early as spring.
‘This is a pivotal moment in the development of our Covid-19 vaccine candidate,’ Moderna CEO Stéphane Bancel said. ‘Since early January, we have chased this virus with the intent to protect as many people around the world as possible.’
‘All along, we have known that each day matters,’ she said. ‘This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease.’
‘We look forward to the next milestones of submitting for an EUA in the US and regulatory filings in countries around the world, while we continue to collect data on the safety and efficacy of the vaccine in the COVE study,’ she added.
Moderna shares are trading 9% higher on Monday at the time of publication, with the stock up 406% year-to-date.
Synairgen’s new drug could accelerate Covid-19 recovery
Southampton-based biotech company, Synairgen, developed a naturally produced protein which helps the body fight viral infections. The company also said the drug ‘may have the potential as an inhaled drug to restore the lung's immune response and accelerate recovery from Covid-19’
‘The results confirm our belief that interferon beta, a widely known drug approved for use in its injectable form for other indications, may have the potential as an inhaled drug to restore the lung’s immune response and accelerate recovery from COVID-19,’ Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Lead Author, said.
‘This pH neutral, inhaled interferon beta-1a formulation (SNG001) provides high, local concentrations of the immune protein which boosts lung defences rather than targeting specific viral mechanisms,’ he said.
‘This might carry additional advantages of treating Covid-19 when it occurs alongside infection by another respiratory virus such as influenza or Respiratory Syncytial Virus that may well be encountered in the winter months,’ Wilkinson added.
Will the world have a vaccine in 2020?
The vaccine candidate is one of many that governments hope to fast-track approval for using emergency powers, and Pfizer and BioNTech have said they will be in a position to publish the data needed to get the green light from the US Food & Drug Administration ‘by the third week of November’.
Although the candidate could be the first widely accepted vaccine to be approved, the trial will continue to monitor participants for the next two years to ensure it is safe over the long term. Meanwhile, the pair are drawing up plans to outline how the vaccine will be produced if its approved.
Ultimately, if everything goes to plan, the pair are hoping to produce up to 50 million doses of the vaccine by the end of 2020, before raising the stakes by producing 1.3 billion doses in 2021. It is important to remember that the trial suggests people will need two doses of the vaccine for it to work, meaning there is only enough capacity at present to potentially treat around 650 million people by the end of next year.
How to trade stocks with IG
- Create an IG trading account or log in to your existing account
- Enter ‘Moderna Inc’ in the search bar and select it
- Choose your position size
- Click on ‘buy’ or ‘sell’ in the deal ticket
- Confirm the trade
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Act on share opportunities today
Go long or short on thousands of international stocks with spread bets and CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Take your position
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
You might be interested in…
Find out what charges your trades could incur with our transparent fee structure.
Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.
Stay on top of upcoming market-moving events with our customisable economic calendar.